To include your compound in the COVID-19 Resource Center, submit it here.

Helsinn, MEI start Phase III AML study of pracinostat

Helsinn Healthcare S.A. (Lugano, Switzerland) and MEI Pharma Inc. (NASDAQ:MEIP) began a Phase III trial of

Read the full 168 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE